ArticleBritish journal of cancer2018

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.

Helena Polena et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.